CoChat

Brivaracetam in Unverricht‐Lundborg disease (EPM 1): Results from two randomized, double‐blind, placebo‐controlled studies

Open access
Kälviäinen, Reetta, Genton, Pierre, Andermann, Eva, Andermann, Frederick, Magaudda, Adriana, Frucht, Steven J., Schlit, Anne‐Françoise, Gerard, Danielle, de la Loge, Christine, von Rosenstiel, Philipp · 2016 · Epilepsia
Cited by 53

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Summary: Objective: To evaluate efficacy, tolerability, and safety of adjunctive brivaracetam (BRV) in patients with Unverricht‐Lundborg disease (EPM 1). Methods: Two prospective, multicenter, double‐blind, phase III trials (N01187/NCT 00357669; N01236/NCT 00368251) in patients (≥16 years) with genetically ascertained EPM 1, showing moderate–severe myoclonus (action myoclonus score ≥30/160), randomized (1:1:1) to twice‐daily BRV (N01187: 50 or 150 mg/day; N01236: 5 or 150 mg/day), or placebo. Both studies comprised a baseline period (2 weeks), 2‐week up‐titration period, 12‐week stable‐dose maintenance period, and down‐titration or entry into long‐term follow‐up study. Symptoms of myoclonus were assessed by Unified Myoclonus Rating Scale (UMRS). Primary efficacy end point was percent reduction from baseline in action myoclonus score (UMRS section 4) at last treatment visit. Safety assessments included treatment‐emergent adverse events (TEAE s). Results: N01187: 50 patients randomized, 47 completed; N01236: 56 patients randomized, 54 completed. Median (min–max) percent reduction from baseline in action myoclonus score is the following—N01187: placebo 5.6 (−81.3 to 53.8), pooled BRV group (primary efficacy analysis) 21.4 (−50.0 to 73.6), BRV 50 mg/day 26.3 (−35.8 to 69.2), BRV 150 mg/day 16.9 (−50.0 to 73.6); N01236: placebo 17.5 (−170 to 61.5), BRV 5 mg/day −4.6 (−430 to 81.8), BRV 150 mg/day (primary efficacy analysis) 12.3 (−58.3 to 96.9). Estimated differences versus placebo were not statistically significant. TEAE s were reported by 72–75% placebo‐treated and 56–83% BRV‐treated patients. Significance: Effect of BRV on action myoclonus was not statistically significant. However, action myoclonus score showed wide intrapatient variability and may not have been the optimal tool to measure severity of myoclonus in EPM 1. Both studies had very high completion rates (95.3% overall), and a high percentage of patients (88.7% overall) entered long‐term follow‐up; both likely to be influenced by good tolerability. These studies demonstrate the feasibility of rigorous trials in progressive myoclonic epilepsy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/epi.13275

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 53

Metadata

Authors
Kälviäinen, R., Genton, P., Andermann, E., Andermann, F., Magaudda, A., Frucht, S. J., Schlit, A., Gerard, D., de la Loge, C., & von Rosenstiel, P.
Venue
Epilepsia
Publisher
Wiley
Published
2015-12-15
Volume
57
Issue
2
Pages
210-221
ISSN
  • 0013-9580 (ISSN-L)
  • 1528-1167
OpenAlex
W2210712732
Cited by
53
References
1
FWCI
5.07
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.